Loading...

MedXY AI/MedXY News/Tag: Cardiology

MedXY News

EnglishTag

Cardiology

89 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16

Twice-Yearly Inclisiran Successfully Lowers LDL-C in Adolescents with Heterozygous Familial Hypercholesterolaemia: Insights from ORION-16

The ORION-16 trial demonstrates that inclisiran, a twice-yearly siRNA therapy, significantly and safely reduces LDL cholesterol in adolescents with HeFH, offering a potent new tool for early cardiovascular risk management in high-risk pedia

Section: CardiologyFeb 25, 2026

Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China

Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China

A multicentre RCT in China found that pharmacist-led patient self-testing (PST) significantly improves time in therapeutic range and reduces major bleeding and thromboembolism in patients with mechanical heart valves compared to traditional

Section: CardiologyFeb 23, 2026

Challenging the Label: Large-Scale Meta-Analysis Refutes Most Statin-Attributed Adverse Effects

Challenging the Label: Large-Scale Meta-Analysis Refutes Most Statin-Attributed Adverse Effects

A comprehensive meta-analysis of double-blind RCTs by the CTT Collaboration reveals that the majority of adverse effects listed on statin labels, including cognitive and sleep issues, lack causal evidence, suggesting a need for urgent regul

Section: CardiologyFeb 17, 2026

Early Life Origins of Hypertension: Longitudinal Evidence That Blood Pressure Tracks from Birth to School Age

Early Life Origins of Hypertension: Longitudinal Evidence That Blood Pressure Tracks from Birth to School Age

A longitudinal study of the ENVIRONAGE cohort reveals that blood pressure tracks consistently from birth through childhood, with higher neonatal readings significantly increasing the risk of hypertension by age 11, emphasizing the need for

Section: CardiologyFeb 11, 2026

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks

An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours

Section: CardiologyFeb 8, 2026

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Section: CardiologyFeb 4, 2026

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

Circadian Heart Rate Fluctuations: A Potent 21-Year Predictor of Mortality in Patients with Diabetes

A 21-year longitudinal study demonstrates that impaired circadian heart rate fluctuations, measured via 24-hour ambulatory monitoring, significantly predict cardiovascular and all-cause mortality in diabetes, offering a low-cost, accessible

Section: CardiologyFeb 4, 2026

The Multi-Billion Dollar Toll of Chagas Disease: Why Aging Populations and Chronic Cardiac Care are Driving Economic Burden in Latin America

The Multi-Billion Dollar Toll of Chagas Disease: Why Aging Populations and Chronic Cardiac Care are Driving Economic Burden in Latin America

A comprehensive cost-of-illness analysis from the RAISE study reveals that Chagas disease imposes a massive economic burden on Latin American countries, driven by a shift toward chronic cardiac complications in aging populations, despite de

Section: CardiologyJan 30, 2026

PTSD and Sleep Disorders Linked to Sharp Rise in Acute Coronary Syndrome Risk

PTSD and Sleep Disorders Linked to Sharp Rise in Acute Coronary Syndrome Risk

A comprehensive meta-analysis of over 22 million individuals identifies mental disorders, particularly PTSD and sleep disturbances, as major independent risk factors for acute coronary syndrome, urging a paradigm shift toward integrated car

Section: CardiologyJan 27, 2026

AI-ECG Models for Heart Failure Screening Show High Accuracy in First-of-its-Kind Independent Comparison Study

AI-ECG Models for Heart Failure Screening Show High Accuracy in First-of-its-Kind Independent Comparison Study

This independent validation study confirms that AI-enhanced ECG models effectively detect left ventricular systolic dysfunction across diverse populations, achieving AUROCs up to 0.93. However, significant barriers remain regarding model tr

Section: AIJan 26, 2026

Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia

Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia

Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where trad

Section: CardiologyJan 25, 2026

NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?

NT-proBNP-Defined Heart Stress: A New Compass for Individualized Blood Pressure Targets in Older Adults?

A post hoc analysis of the ASPREE trial reveals that heart stress, measured by NT-proBNP, significantly alters the relationship between blood pressure and cardiovascular risk in older adults, suggesting a paradigm shift toward biomarker-gui

Section: CardiologyJan 19, 2026

DOACs After Left Atrial Appendage Closure: Enhancing Safety Without Compromising Efficacy in the ANDES Trial

DOACs After Left Atrial Appendage Closure: Enhancing Safety Without Compromising Efficacy in the ANDES Trial

The ANDES randomized trial demonstrates that 60-day DOAC therapy post-LAAC significantly reduces bleeding events compared to DAPT, while maintaining comparable rates of device-related thrombosis, suggesting a superior safety profile for sho

Section: CardiologyJan 19, 2026

Mechanical Thrombectomy Superior to Anticoagulation Alone for Rapid Right Ventricular Recovery in Intermediate-High Risk Pulmonary Embolism: Results from the STORM-PE Trial

Mechanical Thrombectomy Superior to Anticoagulation Alone for Rapid Right Ventricular Recovery in Intermediate-High Risk Pulmonary Embolism: Results from the STORM-PE Trial

The STORM-PE trial, the first randomized controlled trial of its kind, demonstrates that computer-assisted vacuum thrombectomy (CAVT) significantly improves right ventricular recovery and reduces clot burden compared to anticoagulation alon

Section: CardiologyJan 18, 2026

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT Trial

The TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with compar

Section: CardiologyJan 17, 2026

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is

Section: CardiologyJan 17, 2026

Vericiguat in Compensated HFrEF: Navigating the Complex Results of the VICTOR Trial and the Burden of Outpatient Worsening

Vericiguat in Compensated HFrEF: Navigating the Complex Results of the VICTOR Trial and the Burden of Outpatient Worsening

The VICTOR trial evaluated vericiguat in stable HFrEF outpatients. While the primary endpoint was not met, exploratory analyses revealed significant mortality reductions and highlighted the prognostic importance of outpatient heart failure

Section: CardiologyJan 17, 2026

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial

Tenecteplase Outperforms Alteplase in Mechanical Heart Valve Thrombosis: Insights from the TENET Trial

The TENET randomized clinical trial reveals that tenecteplase bolus administration achieves significantly higher thrombolytic success rates and shorter hospital stays compared to alteplase infusion for mechanical prosthetic valve thrombosis

Section: CardiologyJan 17, 2026

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?

Opportunistic Genomic Screening for Familial Hypercholesterolemia: Does Genetic Feedback Drive Clinical Change?

This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest

Section: CardiologyJan 16, 2026

Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease

Beyond the Arteries: Why Finerenone is a Game-Changer for Diabetic Kidney Disease

The FIVE-STAR trial reveals that finerenone’s cardiorenal benefits stem from reducing internal kidney pressure rather than improving arterial stiffness, offering a new perspective on managing type 2 diabetes and chronic kidney disease.

Section: CardiologyJan 11, 2026

Prev 1 2 3 4 5 Next